TABLE 3.
Attrition of LCMV-specific memory cells following poly(I:C) injection
| Expt | Cell type and treatment receivedd | n | Population | No. of cells (104) (% change) | % Annexin+ |
|---|---|---|---|---|---|
| 1 | LCMV-immune (day 0) | 2 | CD8+ | 589 ± 69.8 | NDa |
| CD8+ CD44hi | 323 ± 123 | ND | |||
| CD8+ CD44lo | 266 ± 53.4 | ND | |||
| CD8+ NP398–404 tetramer+ | 37.1 ± 13.7 | ND | |||
| LCMV-immune + day 1 poly(I:C) | 3 | CD8+ | 262 ± 20.6 (−55)b | ND | |
| CD8+ CD44hi | 109 ± 10.5 (−66)c | ND | |||
| CD8+ CD44lo | 154 ± 25.3 (−42)b | ND | |||
| CD8+ NP396–404 tetramer+ | 7.9 ± 0.6 (−79)b | ND | |||
| 2 | LCMV-immune (day 0) | 3 | CD8+ | 966 ± 273 | 19 ± 10 |
| CD8+ CD44hi | 458 ± 102 | 15 ± 3.7 | |||
| CD8+ CD44lo | 508 ± 180 | 21 ± 15 | |||
| CD8+ NP396–404 tetramer+ | 53.2 ± 2.1 | 63 ± 11 | |||
| LCMV-immune + day 1 poly(I:C) | 4 | CD8+ | 543 ± 189 (−44)c | 14 ± 5.6 | |
| CD8+ CD44hi | 152 ± 28.5 (−66)b | 25 ± 0.5b | |||
| CD8+ CD44lo | 391 ± 163 (−23) | 15 ± 4.3 | |||
| CD8+ NP396–404 tetramer+ | 25.5 ± 6.4 (−52)b | 78 ± 3.1b |
a
ND, not done.
b
P < 0.05 compared to grouped control.
c
P < 0.1 compared to grouped control.
d
Day 0, untreated at that time.